The GLP-1 Cost Question Every Employer Is Asking
GLP-1 medications are now the single largest driver of pharmacy spend for most self-funded employers. List prices exceed $15,000 per patient annually. PBMs report post-rebate net costs that look materially lower. Manufacturers like Lilly and Novo Nordisk are offering direct employer pricing. And a growing number of infrastructure platforms claim to deliver the lowest net cost through a direct channel.
For a benefits director trying to make a fiduciary-sound decision, the question is straightforward: what is the plan actually paying, and is there a lower-cost path that is operationally viable?
The answer depends on comparing real numbers, not marketing claims, from both channels. This article walks through the actual economics.
Why GLP-1 Cost Comparisons Are Harder Than They Look
List price means nothing in this comparison. The relevant number is net cost to the plan after all rebates, fees, spread, and float are accounted for. PBM reporting typically shows a post-rebate net cost, but that number is calculated on a population average, not per prescription. Rebates are held 90 to 180 days before reconciliation. Spread between what the PBM charges the plan and what it pays the pharmacy may not be fully disclosed. The net cost a PBM reports and the actual all-in cost to the plan are frequently different numbers.
On the manufacturer-direct side, pricing is typically fixed and transparent, but there are infrastructure and dispensing fees that must be included in any honest comparison. A self-funded employer evaluating their GLP-1 employer benefit options needs to see the complete cost picture on both sides before drawing conclusions.
The PBM Channel: What Employers Are Actually Paying
WAC for Wegovy is approximately $1,350 per month. Zepbound is approximately $1,060 per month. PBMs negotiate rebates with manufacturers, but for GLP-1s the rebate leverage is lower than in established therapeutic categories because manufacturer demand is high and employer adoption is still growing.
Post-rebate net costs in the PBM channel vary widely by contract, but the average self-funded employer is landing around $750 per member per month after rebates. That figure does not always account fully for spread, dispensing fees, and administrative costs layered on top. The employer may be paying materially more than the rebate-adjusted number suggests.
The timing of rebate reconciliation adds another layer of cost. When rebates are held for 90 to 180 days, the plan is effectively extending an interest-free loan to the PBM. For a plan with 20 members on GLP-1 therapy at $750 per month, that is $15,000 per month in drug spend where the rebate portion remains in the PBM's hands for one to two quarters before any reconciliation occurs. The actual rebate amount that reaches the plan may also differ from the projected amount due to manufacturer contract adjustments, utilization mix changes, and clawback provisions that are difficult for the employer to audit independently.
Benefits directors reviewing their GLP-1 employer benefit costs should request a complete accounting that separates WAC, rebate credits, spread, dispensing fees, and administrative charges for each GLP-1 drug in their formulary. Without that level of granularity, the reported net cost is an estimate, not a verified number.
The Manufacturer-Direct Channel: What the Numbers Look Like
Lilly's Employer Connect program prices Zepbound at $449 per month for all doses, but employers should account for a $55 dispensing fee charged by Lilly's exclusive pharmacy partners, bringing the all-in cost to approximately $504 per member per month.
Novo Nordisk's direct employer program for Wegovy prices at $499 per month with prior authorization requirements, or $349 per month without PA for plans that prefer a lower-friction access model.
These are fixed, transparent prices. There is no rebate hold period, no spread, and no quarterly reconciliation. The employer knows the cost at the point of dispense. This is manufacturer-direct drug pricing in its simplest form: a contracted price applied at the point of transaction.
Compared to the PBM average of approximately $750 per member per month, the savings range from roughly $246 to $400 per patient per month depending on the drug and program selected. At 20 members on GLP-1 therapy, that represents $59,000 to $96,000 in annual savings on those prescriptions alone.
What a Valid Cost Comparison Requires
A valid comparison between PBM and manufacturer-direct channels requires evaluating the same drug, the same member population, and the same time period, with all fees accounted for on both sides.
The manufacturer-direct channel has infrastructure fees. The pharmacy benefit infrastructure platform facilitating eRx intake, eligibility, fulfillment routing, and settlement charges an administrative fee per prescription. Those fees must be included in the all-in cost. A comparison that ignores platform fees on the direct side is as misleading as one that ignores spread on the PBM side.
The PBM channel has rebates, but also spread, dispensing fees, and administrative costs that may not be fully visible in standard reporting. CAA 2026 requires PBMs to disclose all direct and indirect compensation, which should make these costs more transparent. But even with full disclosure, the employer needs to calculate actual per-prescription net cost, not rely on a summary report that averages across the entire formulary.
Plan sponsors should demand a complete per-prescription cost comparison, not a list-price-minus-rebate estimate from either side. The only way to know which channel produces the lowest net cost for a specific drug and a specific member is to compare the complete economics at the transaction level.
The Fiduciary Dimension
For a self-funded employer, choosing between channels is not just a financial decision. It is a fiduciary one. CAA 2026 and ERISA require plan sponsors to act in the interest of plan participants and to document that each benefit decision was prudently made.
A plan that has access to a manufacturer-direct channel offering materially lower net cost and does not evaluate it faces a defensibility question. If GLP-1 prescriptions represent $180,000 or more in annual plan spend, and a direct channel reduces that by $59,000 to $96,000, the decision to remain exclusively in the PBM channel requires documented justification.
The prudent expert standard does not require adopting every new model. It requires evaluating available alternatives and documenting the rationale for the decision made. For GLP-1 employer benefit decisions specifically, where the cost differential between channels can exceed 30 percent, that documentation requirement is not theoretical. It is the kind of decision a regulator or plaintiff would examine closely. The self-funded employer that can produce a per-prescription comparison showing they evaluated both channels and selected the lower-cost option is in a defensible position. The one that cannot produce that comparison is not.
What to Look For in a Direct Channel
Not all direct channels are equivalent. Some are clinical wrappers that negotiate a discount but do not operate as genuine pharmacy benefit infrastructure. Key questions to ask: Is the platform pharmacy-licensed? Does it produce decision-level documentation for every prescription? Does it evaluate all available channels in real time, including standard supply channels, and route to the lowest net cost regardless of which channel wins? Does it integrate with the existing TPA for claims and accumulator reporting?
A platform that meets these criteria operates as genuine benefit infrastructure. One that does not is a parallel vendor workflow sitting outside the benefit. The distinction matters because prescriptions processed outside the benefit do not count toward member deductibles and accumulators, creating a fragmented experience that is difficult to administer and harder to defend as a fiduciary decision.
The strongest position for a self-funded employer is a platform that evaluates every channel on every prescription, routes to the lowest net cost, and documents the decision. That approach produces savings when the direct channel wins and preserves the PBM channel when it is the better option. It also produces the per-prescription documentation that satisfies ERISA's prudent expert standard.
Evaluating Every Channel on Every Prescription
ApalyRx evaluates GLP-1 prescriptions across all available channels in real time, including manufacturer-direct drug pricing from Lilly and Novo Nordisk, and routes to the lowest net cost with decision-level documentation for every script. For self-funded employers seeking to optimize their GLP-1 employer benefit spend with full fiduciary documentation, learn how the platform works.